
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Aptar
Deal Size : Undisclosed
Deal Type : Agreement
Nasus Announces Expanded Agreement to Support Development and Commercialization of NS002
Details : As part of the agreement, Epinephrine, a hormone targeting adrenergic receptors, will focus on addressing anaphylaxis.
Product Name : NS002
Product Type : Hormone
Upfront Cash : Undisclosed
October 08, 2025
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Aptar
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Laidlaw & Company
Deal Size : $10.0 million
Deal Type : Public Offering
Nasus Pharma Announces Closing of Initial Public Offering
Details : The Company intends to use the net proceeds to develop further its intranasal Epinephrine program, NS002, which is being developed for patients with anaphylaxis.
Product Name : NS002
Product Type : Hormone
Upfront Cash : Undisclosed
August 14, 2025
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Laidlaw & Company
Deal Size : $10.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FMXIN002 in Patients at Risk of Anaphylaxis
Details : Epinephrine is a Hormone drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Anaphylaxis.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
July 01, 2025
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Hadassah Medical Organization | Medis | Pharma Medica Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparative Bioavailability of Intranasal Epinephrine
Details : Epinephrine is a Hormone drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Anaphylaxis.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
January 12, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Hadassah Medical Organization | Medis | Pharma Medica Research
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FMXIN002 (epinephrine) is an adrenergic receptor agonist small molecule drug candidate, which is currently being evaluated for the treatment of anaphylaxis via intranasal spray.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
December 05, 2023
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hydroxypropyl Methyl Cellulose
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Taffix® Regains Marketing Approval in Spain
Details : Taffix powder creates a unique thin acidified gel above the nasal mucosa that lasts 5 hours, significantly shielding the nasal cells from inhaled viruses through both mechanical and chemical protection.
Product Name : TaffiX
Product Type : Carbohydrate
Upfront Cash : Inapplicable
August 16, 2021
Lead Product(s) : Hydroxypropyl Methyl Cellulose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hydroxypropyl Methyl Cellulose
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Taffix® Regains Marketing Approval in Spain
Details : Taffix® powder creates a unique thin acidified gel above the nasal mucosa that lasts 5 hours, significantly shielding the nasal cells from inhaled viruses through both mechanical and chemical protection.
Product Name : Taffix
Product Type : Carbohydrate
Upfront Cash : Inapplicable
August 16, 2021
Lead Product(s) : Hydroxypropyl Methyl Cellulose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : FMXIN001
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder
Details : FMXIN001 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Opiate Overdose.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 19, 2021
Lead Product(s) : FMXIN001
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability of Nasal Epinephrine
Details : Epinephrine is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anaphylaxis.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
January 06, 2021
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hydroxypropyl Methyl Cellulose
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data from a prospective clinical post marketing users survey shows that TaffixTM effectively blocks viruses from reaching nasal mucosa and was able to reduce infection rate of SARS-CoV-2 virus after super spread event by at least 4 fold.
Product Name : TaffiX
Product Type : Carbohydrate
Upfront Cash : Inapplicable
October 13, 2020
Lead Product(s) : Hydroxypropyl Methyl Cellulose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
